Key facts
- It has raised $17.9M across 1 recorded rounds; the latest was Later Stage VC in Dec 2025.
- Notable investors include University of California, Checkmate Capital, KT, KidsX, KidsX Accelerator — 7 tracked in total.
- NeuroSigma has filed 4 Form Ds with the SEC since 2010, most recently Aug 2016 ($11.7M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for NeuroSigma
Funding rounds
1 roundsAbout NeuroSigma
Developer of a non-invasive neurostimulation medical device designed for the treatment of pediatric attention deficit hyperactivity disorder. The company's platform delivers low-level electrical stimulation through external electrodes placed on the forehead to target the trigeminal nerve, operates without surgery, implants, or medication, is prescribed for supervised home use during sleep, enabling pediatric neurology and behavioral health providers to offer a non-pharmacological treatment option for children.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2008
- Employees
- 9
- Website
- neurosigma.com/
- Ownership
- Privately Held (backing)
NeuroSigma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroSigma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroSigma in its N-PORT filings yet. We sweep new filings monthly.